{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:58:41Z","timestamp":1769245121444,"version":"3.49.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We evaluated the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in transplant-na\u00efve patients with relapsed\/refractory Hodgkin lymphoma (HL) who failed to attain metabolic complete response (mCR) to 1 to 2 lines of salvage chemotherapyThose with residual but nonprogressive disease assessed by positron emission tomography\/computed tomography scanning were eligible. An additional 1 to 2 cycles of salvage therapy were permissible in those with progressive disease or when required to bridge to allo-HSCT, with additional imaging at baseline before transplantation. Conditioning consisted of carmustine, etoposide, cytarabine, melphalan, and alemtuzumab. Donor lymphocyte infusions (DLI) were administered for mixed chimerism or residual or relapsed disease. Eleven patients had sibling donors, 13 had HLA-matched unrelated donors, and 7 had HLA-mismatched unrelated donors. There were no graft failures, and no episodes of grade 4 acute graft-versus-host disease (GVHD); only 19.4% of patients had grade 2 to 3 GVHD, and 22.2% had extensive chronic GVHD. The non-relapse mortality rate was 16.1% (95% confidence interval [CI], 7.1%-34.5%). Relapse incidence was 18.7% (95% CI, 8.2%-39.2%). The study met its primary objective, with a 3-year progression-free survival of 67.7% (95% CI, 48.4%-81.2%). Survival outcomes were equivalent in those with residual metabolically active disease immediately before transplantation (n = 24 [70.8%; 95% CI, 17.2%-83.7%]). Two of the 5 patients who relapsed received DLI and remained in mCR at latest follow-up, with a 3-year overall survival of 80.7% (95% CI, 61.9%-90.8%). We demonstrate encouraging results that establish a potential role for allo-HSCT in selected high-risk patients with HL. This trial was registered at www.clinicaltrials.gov as #NCT00908180.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001016","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T17:26:02Z","timestamp":1577121962000},"page":"4264-4270","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Allo-HSCT in transplant-na\u00efve patients with Hodgkin lymphoma: a single-arm, multicenter study"],"prefix":"10.1182","volume":"3","author":[{"given":"Emma","family":"Das-Gupta","sequence":"first","affiliation":[{"name":"Nottingham University Hospital, Nottingham, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty J.","family":"Thomson","sequence":"additional","affiliation":[{"name":"University College London (UCL) Hospitals National Health Service (NHS) Trust, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian J. C.","family":"Bloor","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Clark","sequence":"additional","affiliation":[{"name":"Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Mackinnon","sequence":"additional","affiliation":[{"name":"Royal Free Hospital, London, United Kingdom;"},{"name":"Department of Haematology, UCL Cancer Institute, London, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Kayani","sequence":"additional","affiliation":[{"name":"University College London (UCL) Hospitals National Health Service (NHS) Trust, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Clifton-Hadley","sequence":"additional","affiliation":[{"name":"Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pip","family":"Patrick","sequence":"additional","affiliation":[{"name":"Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadjet","family":"El-Mehidi","sequence":"additional","affiliation":[{"name":"Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Lawrie","sequence":"additional","affiliation":[{"name":"Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy A.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[{"name":"Nottingham University Hospital, Nottingham, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Linch","sequence":"additional","affiliation":[{"name":"University College London (UCL) Hospitals National Health Service (NHS) Trust, London, United Kingdom;"},{"name":"Department of Haematology, UCL Cancer Institute, London, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl S.","family":"Peggs","sequence":"additional","affiliation":[{"name":"University College London (UCL) Hospitals National Health Service (NHS) Trust, London, United Kingdom;"},{"name":"Department of Haematology, UCL Cancer Institute, London, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"issue":"9323","key":"2020012213195362300_B1","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"2020012213195362300_B2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bmt.1700838","article-title":"Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin\u2019s disease: analysis of 280 patients from the French registry. Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle","volume":"20","author":"Brice","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2020012213195362300_B3","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","article-title":"Autologous stem-cell transplantation for Hodgkin\u2019s disease: results and prognostic factors in 494 patients from the Grupo Espa\u00f1ol de Linfomas\/Transplante Aut\u00f3logo de M\u00e9dula Osea Spanish Cooperative Group","volume":"19","author":"Sureda","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020012213195362300_B4","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"2020012213195362300_B5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjh.14245","article-title":"Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation","volume":"175","author":"Shah","year":"2016","journal-title":"Br J Haematol"},{"issue":"23","key":"2020012213195362300_B6","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"key":"2020012213195362300_B7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/asheducation-2016.1.331","article-title":"Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma","volume":"2016","author":"Moskowitz","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9475","key":"2020012213195362300_B8","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","article-title":"Clinical evidence of a graft-versus-Hodgkin\u2019s-lymphoma effect after reduced-intensity allogeneic transplantation","volume":"365","author":"Peggs","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"2020012213195362300_B9","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.bbmt.2016.03.034","article-title":"Impact of pretransplantation (18)F-fluorodeoxyglucose-positron emission tomography on survival outcomes after T cell-depleted allogeneic transplantation for Hodgkin lymphoma","volume":"22","author":"Reyal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"30","key":"2020012213195362300_B10","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020012213195362300_B11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","article-title":"Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin\u2019s lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Genadieva-Stavrik","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"2020012213195362300_B12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"2020012213195362300_B13","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2012.318","article-title":"A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma","volume":"27","author":"Thomson","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2020012213195362300_B14","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2020012213195362300_B15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"2020012213195362300_B16","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"18","key":"2020012213195362300_B17","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2020012213195362300_B18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/bloodadvances.2017011122","article-title":"Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?","volume":"2","author":"Peggs","year":"2018","journal-title":"Blood Adv"},{"issue":"9980","key":"2020012213195362300_B19","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"2020012213195362300_B20","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/24\/4264\/1549966\/advancesadv2019001016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/24\/4264\/1549966\/advancesadv2019001016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T18:20:03Z","timestamp":1579717203000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/24\/4264\/429988\/AlloHSCT-in-transplantna%C3%AFve-patients-with-Hodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":20,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001016","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,23]]}}}